TDOC / Teladoc Health, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 155 E 44th Street, Suite 1700 New York, New York 10017 (Address of Principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2026 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TE

Teladoc Health Reports First Quarter 2026 Results

Exhibit 99.1 Teladoc Health Reports First Quarter 2026 Results NEW YORK, April 29, 2026— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 (“First Quarter 2026”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2025 (“First Quarter 2025”). Highlights

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 29, 2026 Teladoc Health, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 29, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

Exhibit 99.1 Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors NEW YORK, March 30, 2026 - Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workfor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2026 Teladoc Health, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04

As filed with the Securities and Exchange Commission on February 26, 2026

As filed with the Securities and Exchange Commission on February 26, 2026 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH

Subsidiaries of Teladoc Health, Inc.

Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction Advance Medical, Inc. Massachusetts Advanced Medical Healthcare Management Consulting (Shanghai) Co., Ltd. China AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors, Inc. Delaware Bett

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Teladoc Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 6,850,000 $ 4.60 $ 31,510,000.00 0.0001381 $ 4,351.53 Total Offer

Teladoc Health Reports Fourth Quarter and Full Year 2025 Results

Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2025 Results NEW YORK, NY, February 25, 2026— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth Quarter 2025”) and full year ended December 31, 2025 (“Full Year 2025”). Unless otherwise noted, percentage and other changes are re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 25, 2026 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 25, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors

Exhibit 99.1 Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors NEW YORK, February 18, 2026 - Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic tran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2026 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2026 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2026 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2025 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

As filed with the Securities and Exchange Commission on December 12, 2025

As filed with the Securities and Exchange Commission on December 12, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Teladoc Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 1,780,000 $ 7.60 $ 13,528,000.00 0.0001381 $ 1,868.22 Total Offer

THIRD AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN

Exhibit 10.1 THIRD AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN The 2023 Employment Inducement Incentive Award Plan (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, effective as of December 9, 2025 (the “Effective Date”), as follows: 1.Amendment to Section 11.27 of the Plan. Section 11.27 of the Plan is hereby del

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) December 9, 2025 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) December 9, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747

Teladoc Health Reports Third Quarter 2025 Results

Exhibit 99.1 Teladoc Health Reports Third Quarter 2025 Results NEW YORK, NY, October 29, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2024 (“Third Quarter 2024”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 29, 2025 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 29, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

Teladoc Health Announces Chief Financial Officer Transition Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook

Exhibit 99.1 Teladoc Health Announces Chief Financial Officer Transition Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook NEW YORK, Oct. 23, 2025 - Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2025 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

144

144 0001347535 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 DIVITA CHARLES III Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 16787 127435.15 176690662 09/11/2025 NYSE Common 09/10/2025 Restricted Stock Vesting Issuer N 16787 09/10/2025 Compensation Y Sale includes an amount necessary t

144

144 0002037547 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Rodrigues Fernando M. Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 4149 31490.91 176690662 09/03/2025 NYSE Common 09/01/2025 Restricted Stock Vesting Issuer N 4149 09/01/2025 Compensation N FERNANDO MADEIRA RODRIGUES 155 E 44th Street

144

144 0002037711 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Nueno Carlos Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 3998 30326.03 176690662 09/02/2025 NYSE Common 08/29/2025 Restricted Stock Vesting Issuer N 3998 08/29/2025 Compensation N Carlos Nueno 155 E 44th Street, Floor 17 New York NY

144

144 0001780955 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Murthy Mala Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 12846 97440.77 176690662 09/02/2025 NYSE Common 08/29/2025 Restricted Stock Vesting Issuer N 12846 08/29/2025 Compensation N Mala Murthy 155 E 44th Street, Floor 17 New York NY

144

144 0001375088 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Vandervoort Adam C Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 5867 44502.95 176690662 09/02/2025 NYSE Common 08/29/2025 Restricted Stock Vesting Issuer N 5867 08/29/2025 Compensation N Adam Vandervoort 155 E 44th Street Floor 17 New

144

144 0002036989 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Bliss Kelly Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 4700 35650.91 176690662 09/02/2025 NYSE Common 08/29/2025 Restricted Stock Vesting Issuer N 4700 08/29/2025 Compensation N Kelly Bliss 155 E 44th Street Floor 17 New York NY 100

144

144 0002037547 XXXXXXXX LIVE 0001477449 Teladoc Health, Inc. 001-37477 155 E 44TH STREET FLOOR 17 NEW YORK NY 10017 2036352002 Rodrigues Fernando M. Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2383 18075.77 176690662 09/02/2025 NYSE Common 08/29/2025 Restricted Stock Vesting Issuer N 2383 08/29/2025 Compensation N Fernando Madeira Rodrigues 155 E 44th Street

Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (as amended and restated effective May 14, 2025).

Exhibit 10.2 ARTICLE I. PURPOSE The purposes of this Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Teladoc Health, Inc., a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 29, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

Teladoc Health Reports Second Quarter 2025 Results

Exhibit 99.1 Teladoc Health Reports Second Quarter 2025 Results NEW YORK, NY, July 29, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”). Highlig

Credit Agreement, dated July 17, 2025, among Teladoc Health, Inc., JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender, and the lenders party thereto.

Exhibit 10.1 CREDIT AGREEMENT dated as of July 17, 2025 among TELADOC HEALTH, INC., as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A., as Administrative Agent, Issuing Bank and Swingline Lender and JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION, TRUIST SECURITIES, INC. AND ROYAL BANK OF CANADA as Joint Lead Arrangers and Joint Bookrunners TABLE OF CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2025 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 155 E 44th Street, Floor 17 New York, New York 10017 (Address of Principal

First Amendment to Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.1 FIRST AMENDMENT TO TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN The 2023 Incentive Award Plan (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, subject to the approval of the Company’s shareholders, effective as of May 22, 2025 (the “Amendment Effective Date”), as follows: 1.Amendment to Section 11.26 of the Plan. Section 11.26 of the P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES DRAFT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES DRAFT SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 30, 2025 Teladoc Health, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 30, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04

Teladoc Health Reports First Quarter 2025 Results

Exhibit 99.1 Teladoc Health Reports First Quarter 2025 Results PURCHASE, NY, April 30, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2024 (“First Quarter 2024”). First Q

ARS

ANNUAL REPORTOur values We are passionate about taking care of people. We are committed to unsurpassed quality . We keep our promises. We lead with integrity , accountability and transparency . We stand up for what’s right. We strive to create value. We respect each other and value succeeding together .A Letter from Charles (Chuck) Divita, III Chief Executive Officer, Teladoc Health, Inc. T eladoc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Services Agreement, dated May 31, 2018, by and between Teladoc Health International, S.A.U. (formerly Advance Medical Healthcare Management Services, S.A.) and Carlos Nueno.

Exhibit 10.48 Execution Version 31 May 2018 ADVANCE MEDICAL HEALTH-CARE MANAGEMENT SERVICES, S.A. (as Company) and Mr Nueno (as Executive Director) SERVICES AGREEMENT Barcelona, on 31 May 2018 THE PARTIES On the one part, ADVANCE MEDICAL HEALTH-CARE MANAGEMENT SERVICES, S.A., a company organized and existing under the laws of Spain, registered with the Commercial Registry of Barcelona with registe

Teladoc Health, Inc. Insider Trading Compliance Policy

Exhibit 19.1 Effective February 17, 2023 TELADOC HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY I. SUMMARY Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Teladoc Health, Inc. (together with its subsidiaries, the “Company”), as well as that of all persons affiliated with the Company. “Insider trading” is a crime, and occurs whe

Executive Severance Agreement, dated July 14, 2017, by and between Teladoc Health, Inc. and Kelly Bliss.

Exhibit 10.45 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement (“Agreement”) is made effective as of July 14, 2017 (“Effective Date”), by and between Teladoc, Inc. (the “Company”) and Ms. Kelly Bliss, an individual resident in the Commonwealth of Massachusetts (“Executive”). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein

Specimen stock certificate evidencing shares of common stock.

COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS. CUSIP 87918A 10 5 FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF TELADOC HEALTH, INC. transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certificate and the shares represented hereby are subject to the laws of the State of Delawar

Filing Fee Table.

Calculation of Filing Fee Tables S-8 Teladoc Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 1,000,000 $ 11.51 $ 11,510,000.00 0.0001531 $ 1,762.18 Total Offe

Second Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan.

Exhibit 10.25 SECOND AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN The 2023 Employment Inducement Incentive Award Plan (as amended, the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, effective as of February 27, 2025 (the “Amendment Effective Date”), as follows: 1. Amendment to Section 11.27 of the Plan. Section 11.27

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH

Retention Bonus Agreement, dated April 26, 2024, by and between Teladoc Health, Inc. and Kelly Bliss.

Exhibit 10.47 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Kelly Bliss (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHEREAS,

As filed with the Securities and Exchange Commission on February 27, 2025

As filed with the Securities and Exchange Commission on February 27, 2025 Registration No.

Amendment No. 1 to Executive Severance Agreement, dated April 26, 2024, by and between Teladoc Health, Inc. and Kelly Bliss.

Exhibit 10.46 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Ms. Kelly Bliss, an individual resident in the Commonwealth of Massachusetts (“Executive”), is made as of April 26, 2024. Recitals A. Teladoc and Executive are parties t

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction Advance Medical, Inc. Massachusetts Advanced Medical Healthcare Management Consulting (Shanghai) Co., Ltd. China AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors, Inc. Delaware Bett

Retention Bonus Agreement, dated April 26, 2024, by and between Teladoc Health, Inc. and Carlos Nueno.

Exhibit 10.49 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Carlos Nueno (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHEREAS,

Teladoc Health Reports Full Year and Fourth Quarter 2024 Results

Exhibit 99.1 Teladoc Health Reports Full Year and Fourth Quarter 2024 Results PURCHASE, NY, February 26, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year 2024”) and three months ended December 31, 2024 (“Fourth Quarter 2024”). Unless otherwise noted, percentage and other c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 26, 2025 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 26, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

TDOC / Teladoc Health, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us87918a1051111224.txt us87918a1051111224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747

Release and Separation Agreement, dated as of September 27, 2024, by and between Teladoc Health, Inc. and Michael Waters.

Exhibit 10.1 September 27, 2024 Michael Waters Via e-mail Dear Michael: This letter agreement, (together with the attachments, the “Agreement”), reflects our mutual understanding with respect to your future services and expected separation from Teladoc Health, Inc., a Delaware corporation (the “Company” or “we”) and sets forth the payments and benefits that you will be eligible to receive under th

Teladoc Health Reports Third Quarter 2024 Results

Exhibit 99.1 Teladoc Health Reports Third Quarter 2024 Results PURCHASE, NY, October 30, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 (“Third Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2023 (“Third

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 30, 2024 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 30, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

TDOC / Teladoc Health, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us87918a1051102324.txt us87918a1051102324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 27, 2024 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 27, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2024 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number)

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p24-2746exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a

TDOC / Teladoc Health, Inc. / Point72 Asset Management, L.P. - TELADOC HEALTH, INC. Passive Investment

SC 13G 1 p24-2746sc13g.htm TELADOC HEALTH, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) September 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

Form of Chief Executive Officer Performance Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.4 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL

Chief Executive Officer Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.3 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The C

Teladoc Health Reports Second Quarter 2024 Results

Exhibit 99.1 Teladoc Health Reports Second Quarter 2024 Results PURCHASE, NY, July 31, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 (“Second Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 (“Second Quarter 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 31, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 31, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

TDOC / Teladoc Health, Inc. / BlackRock Inc. Passive Investment

us87918a1051070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

As filed with the Securities and Exchange Commission on June 18, 2024

As filed with the Securities and Exchange Commission on June 18, 2024 Registration No.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc.

Amendment No. 2 to Executive Severance Agreement, dated June

Exhibit 10.3 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Ms. Mala Murthy, an individual resident in the State of New York (“Executive”), is made as of June 6, 2024. Recitals A.Teladoc and Executive are parties to that certain E

, by and between Teladoc Health, Inc. and Charles Divita

Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of June 10, 2024 (“Effective Date”), by and between Teladoc Health, Inc. (the “Company”) and Mr. Charles Divita (“Executive”). WHEREAS, pursuant to the offer letter by and between Executive and the Company, dated as of June 5, 2024 (the “Offer Letter”), Executive has agreed to serve as

, 2024, by and between Teladoc Health, Inc. and Charles D

Exhibit 10.1 EXECUTION VERSION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. June 5, 2024 Charles Divita via e-mail Dear Chuck, We are pleased to confirm our offer of employment to you with Teladoc Health, Inc. (“Telad

Teladoc Health Names Chuck Divita as CEO Experienced Healthcare Leader to Head Global Virtual Care Company

Exhibit 99.1 Teladoc Health Names Chuck Divita as CEO Experienced Healthcare Leader to Head Global Virtual Care Company PURCHASE, NY, June 10, 2024 - Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that its Board of Directors has appointed Charles “Chuck” Divita, III, as Chief Executive Officer, effective immediately. Concurrent with his role as C

First Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan.

Exhibit 10.4 FIRST AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN The 2023 Employment Inducement Incentive Award Plan (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, effective as of June 10, 2024 (the “Effective Date”), as follows: 1.Amendment to Section 11.27 of the Plan. Section 11.27 of the Plan is hereby delete

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) June 5, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) June 5, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2 Manhattanville Road, Suite 203 Purchase, New York 10577 (Address of Princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3

Release and Separation Agreement, dated as of April 11, 2024, by and between Teladoc Health, Inc. and Jason Gorevic.

Exhibit 10.2 TELADOC HEALTH, INC. April 11, 2024 Jason Gorevic Via e-mail Re: Release and Separation Agreement Dear Jason: Your last day of employment with Teladoc Health, Inc. (the “Company”) was April 5, 2024 (“Separation Date”). In order to receive the separation benefits provided in Section 5(b)(i) of the Amended and Restated Executive Employment Agreement between you and the Company, dated as

, 2024, by and between Teladoc Health, Inc. and

Exhibit 10.3 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Adam Vandervoort (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHERE

April 26, 2024, by and between Teladoc Health, Inc. and Adam Vandervoort.

Exhibit 10.4 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Adam Vandervoort, an individual resident in the State of Connecticut (“Executive”), is made as of April 26, 2024. Recitals A. Teladoc and Executive are parties to tha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TE

Letter Agreement, dated as of April 1, 2024, by and between Teladoc Health, Inc. and Mala Murthy.

Exhibit 10.1 TELADOC HEALTH, INC. April 1, 2024 Mala Murthy via e-mail Re: Interim CEO Dear Mala: We are pleased that you have agreed to serve as the Interim Chief Executive Officer (“Interim CEO”) of Teladoc Health, Inc. (the “Company”) effective April 5, 2024. The purpose of this letter agreement (the “Letter Agreement”) is to document your duties and the compensation that you will receive for y

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 25, 2024 Teladoc Health, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 25, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04

Teladoc Health Reports First Quarter 2024 Results

Exhibit 99.1 Teladoc Health Reports First Quarter 2024 Results PURCHASE, NY, April 25, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 (“First Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 (“First Quarter 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

ARS

Annual Report 2023Our values We are passionate about taking care of people. We are committed to unsurpassed quality. We keep our promises. We lead with integrity , accountability and transparency. We stand up for what’s right. We strive to create value. We respect each other and value succeeding together.UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 5, 2024 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 5, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-

Teladoc Health Board of Directors Announces Leadership Transition

Exhibit 99.1 Teladoc Health Board of Directors Announces Leadership Transition •Jason Gorevic to depart the company, effective immediately •CFO Mala Murthy appointed acting chief executive •Teladoc Health reaffirms guidance PURCHASE, NY, April 5, 2024 (GLOBE NEWSWIRE) - Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departin

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors, Inc. Delaware BetterHelp, Inc. Delaware Centro Médico Virtual Teladoc Health S.P.A. Chile Consu

Separation and Release of Claims Agreement, dated December 1, 2023, by and between Teladoc Health, Inc. and Claus Jensen.

Exhibit 10.37 [Teladoc Health, Inc. Letterhead] December 1, 2023 Claus Jensen [] Re: Separation and Release of Claims Agreement Dear Claus: As we have discussed, your employment with Teladoc Health, Inc. (the “Company”) as Chief Innovation Officer will terminate effective as of December 1, 2023 (“Termination Date”). On your Termination Date, you are to stop all efforts on behalf of the Company. In

Executive Severance Agreement, dated July 15, 2015, by and between Teladoc Health, Inc. and Daniel Trencher.

Exhibit 10.39 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement (''Agreement”) is made effective as of July 15, 2015 ("Effective Date"), by and between Teladoc, Inc. (the "Company") and Daniel Trencher ("Executive"). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein the terms and conditions of Executive's compensation in the

Teladoc Health, Inc. Incentive-Based Compensation Recovery Policy

Exhibit 97.1 September 21, 2023 Teladoc Health, Inc. Incentive-Based Compensation Recovery Policy The Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation ph

Executive Severance Agreement, dated July 15, 2015, by and between Teladoc Health, Inc. and Andrew Turitz

Exhibit 10.41 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement ("Agreement") is made effective as of July 15, 2015 ("Effective Date"), by and between Teladoc, Inc. (the "Company") and Andrew Turitz ("Executive"). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein the terms and conditions of Executive's compensation in the ev

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 8i or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEA

Teladoc Health, Inc. Non-Employee Director Compensation Program (as amended).

Exhibit 10.29 Effective January 1, 2024 TELADOC HEALTH, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Teladoc Health, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be pa

Amendment No. 1 to Executive Severance Agreement, dated October 29, 2019, by and between Teladoc Health, Inc. and Andrew Turitz.

Exhibit 10.42 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Andrew Turitz, an individual resident in the State of Illinois (“Executive”), is made as of October 29, 2019. Recitals A.Teladoc and Executive are parties to that ce

Seventh Amended and Restated Bylaws of Teladoc Health, Inc.

Exhibit 3.2 SEVENTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. (a Delaware corporation) SEVENTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. ARTICLE I CORPORATE OFFICES Section 1.1 REGISTERED OFFICE. The registered office of Teladoc Health, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 20, 2024 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 20, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commiss

Teladoc Health Reports Fourth Quarter and Full Year 2023 Results

Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2023 Results •Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million •Fourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per share •Fourth quarter 2023 adjusted EBITDA increase of 22% to $114.4 million and full ye

TDOC / Teladoc Health, Inc. / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

TDOC / Teladoc Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02047-teladochealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Teladoc Health Inc Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat

TDOC / Teladoc Health, Inc. / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

TDOC / Teladoc Health, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm244117d24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Teladoc Health, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

TDOC / Teladoc Health, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us87918a1051012624.txt us87918a1051012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 8, 2023 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 8, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commissi

Form of Performance Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.5 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc

Form of Restricted Stock Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.3 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company has

Form of Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.4 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The C

Form of Stock Option Agreement under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 10.2 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby gran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 24, 2023 Teladoc Health, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 24, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commissi

Teladoc Health Reports Third Quarter 2023 Results

Exhibit 99.1 Teladoc Health Reports Third Quarter 2023 Results •Third quarter 2023 revenue grows 8% year-over-year to $660.2 million •Third quarter 2023 operating cash flow of $105.6 million; free cash flow of $68.0 million •Third quarter 2023 net loss of $57.1 million, or $0.35 per share •Third quarter 2023 adjusted EBITDA of $88.8 million, up 73% year-over-year PURCHASE, NY, October 24, 2023— Te

Teladoc Health Appoints Leading Healthcare and Hospitals Executive Eric Evans to Board of Directors

Exhibit 99.1 Teladoc Health Appoints Leading Healthcare and Hospitals Executive Eric Evans to Board of Directors Purchase, NY, September 20, 2023 – Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company’s board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 20, 2023 Teladoc Health,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 20, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commis

Amendment No. 2 to Executive Severance Agreement, dated June 9, 2023, by and between Teladoc Health, Inc. and Andrew Turitz.

Exhibit 10.9 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Second Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Andrew Turitz, an individual resident in the State of Illinois (“Executive”), is made as of June 9th, 2023. Recitals A. Teladoc and Executive are parties to th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL

Form of Stock Option Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.2 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants to the participant listed below (“Partici

Form of Performance Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.5 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants

Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan.

Exhibit 99.1 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc.

Form of Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.4 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants to the participant list

Amendment No. 1 to Executive Severance Agreement, dated June 9, 2023, by and between Teladoc Health, Inc. and Daniel Trencher.

Exhibit 10.8 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Daniel Trencher, an individual resident in the State of New York (“Executive”), is made as of June 9th, 2023. Recitals A. Teladoc and Executive are parties to that ce

As filed with the Securities and Exchange Commission on July 28, 2023

As filed with the Securities and Exchange Commission on July 28, 2023 Registration No.

Form of Restricted Stock Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.3 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company has granted to the participant listed below (“P

Teladoc Health Reports Second Quarter 2023 Results

Exhibit 99.1 Teladoc Health Reports Second Quarter 2023 Results •Second quarter 2023 revenue grows 10% year-over-year to $652.4 million •Second quarter 2023 operating cash flow of $101.2 million; free cash flow of $64.6 million •Second quarter 2023 net loss of $65.2 million, or $0.40 per share •Second quarter 2023 adjusted EBITDA of $72.2 million PURCHASE, NY, July 25, 2023— Teladoc Health, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 25, 2023 Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 25, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission

TDOC / Teladoc Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: June 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 30, 2023 ( May 25, 2023) Telad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 30, 2023 ( May 25, 2023) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (C

Second Amendment to Teladoc Health, Inc. Amended and Restated Employee Stock Purchase Plan.

Exhibit 10.2 SECOND AMENDMENT TO TELADOC HEALTH, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN The 2015 Employee Stock Purchase Plan, amended and restated as of May 9, 2021, (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby further amended, effective as of May 25, 2023 (the “Effective Date”), as follows: 1. Amendment to Section 3.1 of the Plan. Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2 Manhattanville Road, Suite 203 Purchase, New York 10577 (Address of Princ

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

Teladoc Health, Inc. Level 14 Severance Plan.

Exhibit 10.3 TELADOC HEALTH, INC. LEVEL 14 SEVERANCE PLAN The Company has adopted this Level 14 Severance Plan (the “Plan”) for the benefit of certain management and highly compensated employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intended to help re

Teladoc Health, Inc. 2023 Incentive Award Plan.

Exhibit 10.1 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

Filing Fee Table

EX-FILING FEES 4 tm2317113d2ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

As filed with the Securities and Exchange Commission on May 30, 2023

As filed with the Securities and Exchange Commission on May 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents DeferredTaxAssetsDeferredIncome UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Teladoc Health Reports First Quarter 2023 Results

Exhibit 99.1 Teladoc Health Reports First Quarter 2023 Results ● First quarter 2023 revenue grows 11% year-over-year to $629.2 million ● First quarter 2023 net loss of $69.2 million, or $0.42 per share ● First quarter adjusted EBITDA totaled $52.8 million PURCHASE, NY, April 26, 2023— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial result

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 26, 2023 Te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 26, 2023 Teladoc Health, Inc.

ARS

ANNUAL REPORT 2022 A one-in-a-50-million experienceIn 2022, we hit a big milestone—50 million virtual visits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended.

Exhibit 4.10 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Teladoc Health, Inc. (“Teladoc Health,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share (the “common stock”). As of March 1, 2023, we had 300,000

Home Office Operating Agreement, dated January 1, 2023, by and between Teladoc Health, Inc. and Claus Jensen.

Exhibit 10.25 HOME OFFICE OPERATING AGREEMENT This HOME OFFICE OPERATING AGREEMENT (“Agreement”) is made and entered into effective as of January 1, 2023 (“Effective Date”) by and between: Teladoc Health, Inc., a company organized and existing under the laws of Delaware, with its registered office located at 251 Little Falls Drive, Wilmington, Delaware 19808 (“Teladoc”) and Claus Jensen, an indivi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 8i or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALT

As filed with the Securities and Exchange Commission on March 1, 2023

As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.

Second Supplemental Indenture, dated as of January 1, 2023, among Livongo Health, Inc., Teladoc Health, Inc. and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee.

Exhibit 4.9 EXECUTION VERSION SECOND SUPPLEMENTAL INDENTURE This SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of January 1, 2023, is entered into among Livongo Health, Inc., a Delaware corporation (the “Company”), Teladoc Health, Inc., a Delaware corporation (“Teladoc”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Ass

Offer Letter, dated March 19, 2021, by and between Teladoc Health, Inc. and Claus Jensen.

Exhibit 10.24 2 Manhattanville Road, Suite 203 ⧫ Purchase ⧫ New York 10577 ⧫ (203) 742-1719 March 19, 2021 Claus Jensen ADDRESS: [ ] Dear Claus, We are pleased to confirm our offer of employment to you with Teladoc Health, Inc. for the position of Chief Innovation Officer. Your start date will be April 26, 2021. You will report to Jason Gorevic, CEO. Your work location will be from our Purchase Of

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction AcuteCare Telemedicine, LLC Georgia Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors International Insurance S.a.r.l. Luxembourg Best Doctors, In

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2023 Teladoc Health, Inc.

Teladoc Health Reports Fourth Quarter and Full Year 2022 Results

Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2022 Results ● Fourth quarter revenue grows 15% year-over-year to $637.7 million and full year revenue grows 18% year-over-year to $2,406.8 million ● 2022 full year cash flow from operating activities and free cash flow was $189.3 million and $16.5 million, respectively; Cash position of $918.2 million as of December 31, 2022 ● Fourt

TDOC / Teladoc, Inc. / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047843sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch

TDOC / Teladoc, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

TDOC / Teladoc, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02017-teladochealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designa

TDOC / Teladoc, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us87918a1051020723.txt us87918a1051020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

TDOC / Teladoc, Inc. / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 1 - TELADOC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

Subject: Difficult Steps Towards Integration & Balanced Growth

Exhibit 99.1 Subject: Difficult Steps Towards Integration & Balanced Growth Dear Colleagues, Today we are taking the difficult but necessary step of letting go approximately 300 colleagues or 6% of Teladoc Health’s non-clinician workforce. This is not a decision I take lightly, and we will do all we can to help our colleagues through this moment. One of the first questions you may have is why is t

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 18, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 9, 2023 Teladoc Health, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 9, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents DeferredTaxAssetsDeferredIncome ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Executive Employment Agreement, dated June 15, 2022, by and between Teladoc Health, Inc. and Michael Waters.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into as of June 15, 2022 (the ?Effective Date?), by and between Teladoc Health, Inc. (the ?Company?) and Michael Waters, an individual, residing at [ ] (the ?Executive?). ? 1.Employment. During the period of Executive?s employment with the Company, the Company shall employ Executiv

Executive Employment Agreement, dated October 2, 2022, by and between Teladoc Health, Inc. and Laizer Kornwasser.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of the last date written below (the “Effective Date”), by and between Teladoc Health, Inc. (the “Company”) and Laizer Kornwasser, an individual, residing at [ ] (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive wishes to be employed b

Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets

Exhibit 99.1 Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets PURCHASE, NY, October 24, 2022 - Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Laizer Kornwasser as president, enterprise growth and global markets. In this role, Kornwasser is charged with further unlocking the revenue and profit growth potential of the com

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2022 ( October 24, 2022) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorpora

Teladoc Health Reports Third-Quarter 2022 Results

Exhibit 99.1 Teladoc Health Reports Third-Quarter 2022 Results ● Third quarter revenue grows 17% year-over-year to $611.4 million ● Net loss totaled $73.5 million, or $0.45 per share ● Adjusted EBITDA totaled $51.2 million ● Cash flow from operating activities was $63.0 million for the quarter and $123.7 million year-to-date PURCHASE, NY, October 26, 2022— Teladoc Health, Inc. (NYSE: TDOC), the gl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2022 Teladoc Health, Inc.

LETTER

United States securities and exchange commission logo October 6, 2022 Jason Gorevic Chief Executive Officer Teladoc Health, Inc.

* * * * *

October 3, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance Disclosure Review Program Re: Teladoc Health, Inc.

LETTER

United States securities and exchange commission logo September 20, 2022 Jason Gorevic Chief Executive Officer Teladoc Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents DeferredTaxAssetsDeferredIncome ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Teladoc Health, Inc. Non-Employee Director Compensation Program (as amended).

Exhibit 10.1 ? Effective January 1, 2022 ? TELADOC HEALTH, INC. ? NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM ? Non-employee members of the board of directors (the ?Board?) of Teladoc Health, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shal

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): July 27, 2022 ? ? ? Teladoc Health, Inc.

Teladoc Health Reports Second-Quarter 2022 Results

EX-99.1 2 tdoc-20220727xex99d1.htm EX-99.1 Exhibit 99.1 Teladoc Health Reports Second-Quarter 2022 Results ● Second quarter revenue grows 18% year-over-year to $592.4 million. ● Net loss per share of $19.22, primarily driven by non-cash goodwill impairment charge of $3.0 billion, or $18.78 per share. ● Primary360 adds multiple new clients, and new capabilities, as early momentum continues PURCHASE

Teladoc Health Names Mike Waters as Chief Operating Officer

Exhibit 99.1 Teladoc Health Names Mike Waters as Chief Operating Officer PURCHASE, NY, July 25, 2022 - Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Mike Waters as chief operating officer. As COO, Waters will work closely with Jason Gorevic, CEO of Teladoc Health, on the organization?s overall operations and execution and will take primary responsibility fo

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 25, 2022 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File

Executive Employment Agreement by and between Teladoc Health, Inc. and Michael Waters, dated June 15, 2022.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into as of June 15, 2022 (the ?Effective Date?), by and between Teladoc Health, Inc. (the ?Company?) and Michael Waters, an individual, residing at Michael Waters, 26131 Red Corral Road, Laguna Hills, CA 92653 (the ?Executive?). 1. Employment. During the period of Executive?s emplo

TDOC / Teladoc, Inc. / BAILLIE GIFFORD & CO Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Teladoc Health Inc (Amendment no.3) - (Name of Issuer) COMMON STOCK - (Title of Class of Securities) 87918A105 - (CUSIP Number) 30 June 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 2, 2022 ( May 26, 2022) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (C

Sixth Amended and Restated Bylaws of Teladoc Health, Inc.

Exhibit 3.2 SIXTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. (a Delaware corporation) TABLE OF CONTENTS Page Article I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 Article II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 5 2.5 ADVANCE NOTICE PROCEDURES FOR

Seventh Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.

Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TELADOC HEALTH, INC. Teladoc Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Teladoc Health, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaw

Form of Performance Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2015 Incentive Award Plan.

? Exhibit 10.1 ? TELADOC HEALTH, INC. 2015 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (f/k/a Teladoc, Inc.) (the ?Company?).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2022 Teladoc Health, Inc.

Teladoc Health Reports First Quarter 2022 Results

? Exhibit 99.1 ? Teladoc Health Reports First Quarter 2022 Results ? ? First quarter revenue grows 25% year-over-year to $565.4 million ? ? Net loss per share of $41.58, primarily driven by non-cash goodwill impairment charge of $6.6 billion or $41.11 per share ? ? Full year guidance ranges for 2022 revenue, net loss per share and adjusted EBITDA revised to $2.4 - $2.5 billion, ($43.50) per share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

DEF 14A 1 tm2128566-2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru

TDOC / Teladoc, Inc. / BlackRock Inc. Passive Investment

us87918a1051031122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Subsidiaries of the Registrant.

EX-21.1 2 tdoc-20211231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction AcuteCare Telemedicine, LLC Georgia Advance Medical Health Care Management Services Chile S.A. Chile Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Best Doctors Holdings, Inc. Delaware Best Doctors International Insurance S.a.r.l. Luxem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): February 22, 2022 ? ? ? Teladoc Health, Inc.

Teladoc Health Reports Fourth Quarter and Full Year 2021 Results

Exhibit 99.1 ? Teladoc Health Reports Fourth Quarter and Full Year 2021 Results ? ? Fourth quarter revenue grows 45% year-over-year to $554.2 million and total visits increase 41% to 4.4 million ? ? Full year revenue grows 86% year-over-year to $2,032.7 million and total visits increase 38% to 15.4 million ? ? Full year cash flows from operations grew to $194.0 million ? ? Full year 2022 Revenue g

TDOC / Teladoc, Inc. / Nikko Asset Management Americas, Inc. - SC13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

TDOC / Teladoc, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ?

TDOC / Teladoc, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm225659d45sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

TDOC / Teladoc, Inc. / BlackRock Inc. Passive Investment

SC 13G 1 us87918a1051020822.txt us87918a1051020822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

LETTER

United States securities and exchange commission logo February 8, 2022 Mala Murthy Chief Financial Officer Teladoc Health, Inc.

TDOC / Teladoc, Inc. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

* * * * *

CORRESP 1 filename1.htm February 3, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention:                Division of Corporation Finance Office of Life Sciences Re:          Teladoc Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No: 001-37477 Response Dated January 14, 2022 Dear Ms. Houser and Mr. O

TDOC / Teladoc, Inc. / BAILLIE GIFFORD & CO Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Teladoc Health Inc (Amendment no.2) - (Name of Issuer) COMMON STOCK - (Title of Class of Securities) 87918A105 - (CUSIP Number) 31 December 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

LETTER

United States securities and exchange commission logo January 21, 2022 Mala Murthy Chief Financial Officer Teladoc Health, Inc.

* * * * *

January 14, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance Office of Life Sciences Re: Teladoc Health, Inc.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 10, 2022 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi

LETTER

United States securities and exchange commission logo December 16, 2021 Mala Murthy Chief Financial Officer Teladoc Health, Inc.

This presentation contains, and our officers may make, “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without lim

Exhibit 99.1 This presentation contains, and our officers may make, ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of our business plan and strateg

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 18, 2021 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747

Teladoc Health, Inc. Senior Leader Severance Plan.

Exhibit 10.1 ? TELADOC HEALTH, INC. SENIOR LEADER SEVERANCE PLAN The Company has adopted this Severance Plan (the ?Plan?) for the benefit of certain employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intended to help retain qualified employees, maintain a

Teladoc Health Reports Third-Quarter 2021 Results

Exhibit 99.1 ? Teladoc Health Reports Third-Quarter 2021 Results ? ? Third quarter revenue grows 81% year-over-year to $522 million, updating 2021 revenue outlook to $2,015 million to $2,025 million. ? ? Total third quarter visits top 3.9 million ? 37% higher than Q3 2020. ? ? Significant new agreements with CVS Health and Centene to provide Teladoc Health?s Primary360 to deliver greater care acce

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): October 27, 2021 ? ? ? Teladoc Health, Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 20, 2021 (September 17, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorp

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 16, 2021 (August 13, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporatio

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 4, 2021 (August 3, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Teladoc Health, Inc. 2015 Employee Stock Purchase Plan.

Exhibit 10.1 TELADOC HEALTH, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective May 9, 2021) ARTICLE I. PURPOSE The purposes of this Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of Teladoc Health, Inc., a Delaware corporation (the ?Company?), and its Designated Subsidi

Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance

Exhibit 99.1 ? Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance ? ? Second quarter revenue grows 109% year-over-year to $503 million, driving 2021 revenue outlook increase to $2,000 million to $2,025 million. ? ? Total second quarter visits top 3.5 million ? 28% higher than Q2 2020, in the first wave of the pandemic. ? ? Significant new agreement with HCSC to p

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): July 27, 2021 ? ? Teladoc Health, Inc.

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 16, 2021 (June 16, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 27, 2021 (May 26, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Co

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 18, 2021 (May 17, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Co

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common stock (Title of Class of Securities) (CUSIP Number) April 30,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Form of Performance Restricted Stock Unit Agreements under the Teladoc Health, Inc. 2015 Incentive Award Plan.

? Exhibit 10.1 ? TELADOC HEALTH, INC. 2015 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (f/k/a Teladoc, Inc.) (the ?Company?).

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TE

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): April 28, 2021 ? ? Teladoc Health, Inc.

Teladoc Health Reports First-Quarter 2021 Results

Exhibit 99.1 ? Teladoc Health Reports First-Quarter 2021 Results ? PURCHASE, NY, April 28, 2021??Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2021. ? Highlights ? ? Raises full-year guidance as first quarter revenue grows 151% year-over-year to $453.7 million, with total visits increasing 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) Kinnevik AB (publ) Skeppsbron 18 P.O. Box 2094 SE-103 13 Stockholm, Sweden +46 8 562 000 00 (Name, Address and Telephone

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- DEF 14A

DEF 14A 1 tm212496-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the